In fact, targeting BTK with ibrutinib shows anti-proliferative effects in AML by mediating suppression of FLT3 downstream signaling MAPK, AKT, and NF-κB; and combined inhibition of FLT3 and BTK reportedly has additive anti-leukemia effects (17, 18). This evidence concerns the gene AKT1 and acute myeloid leukemia.